title: The effects of 1% prednisolone acetate on pupil diameter and intraocular pressure in healthy dogs treated with 0.005% latanoprost.
abstract: OBJECTIVE
  Prostaglandin analogs contribute to blood-aqueous barrier breakdown and may exacerbate uveitis. As these analogs induce de novo synthesis of endogenous prostaglandins, their therapeutic, hypotensive effect could potentially be inhibited by anti-inflammatory treatment. We therefore evaluated whether topical 1% prednisolone acetate alters the effects of 0.005% latanoprost on pupil diameter (PD) and intraocular pressure (IOP).
  
  
  METHODS
  Ten healthy Labrador retriever dogs from the Israel Guide Dog Center for the Blind.
  
  
  METHODS
  Pupil diameter and IOP were measured hourly, 8 AM-4 PM, with the right and left eyes serving as control (CE) and treated (TE) eyes, respectively. Measurements were conducted during four sessions: (1) without treatment (n = 10), (2) following latanoprost treatment (n = 10) at 8 AM, (3) following prednisolone treatment (n = 7) at 8 AM, and (4) bilateral latanoprost treatment at 8 AM, prednisolone treatment in TE at 11 AM (n = 8). The different number of dogs in sessions 3 and 4 is because some dogs were matched with their new owners earlier than expected.
  
  
  RESULTS
  Pupil diameters were not affected by the addition of prednisolone and, at 4 PM, were 3.82 ± 0.47 and 3.97 ± 0.36 mm in TE and CE, respectively (P = 0.175, Wilcoxon). IOPs were not affected by the addition of prednisolone and, at 4 PM, were 9.0 ± 0.8 and 9.3 ± 0.8 mm Hg in TE and CE, respectively (P = 0.339, Wilcoxon).
  
  
  CONCLUSIONS
  Prednisolone did not alter latanoprost's miotic and hypotensive effects in normal dogs during this study period.
authors.affiliation: Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, 7610001, Israel.
authors.forename: Nili
authors.initials: N
authors.lastname: Kahane
authors.affiliation: Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, 7610001, Israel.
authors.forename: Tali
authors.initials: T
authors.lastname: Bdolah-Abram
authors.affiliation: Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, 7610001, Israel.
authors.forename: Hilli
authors.initials: H
authors.lastname: Raskansky
authors.affiliation: Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, 7610001, Israel. ron.ofri@mail.huji.ac.il.
authors.forename: Ron
authors.initials: R
authors.lastname: Ofri
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology; D004285:Dogs; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D009184:Mydriatics / Q000008:administration & dosage / Q000494:pharmacology*; D009883:Ophthalmic Solutions; D011239:Prednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D011680:Pupil / Q000187:drug effects* / Q000502:physiology
chemical_list: D000959:Antihypertensive Agents; D009184:Mydriatics; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; C009935:prednisolone acetate; D011239:Prednisolone
keywords: 
  IOP
  ; anti-inflammatory; corticosteroids; glaucoma; prostaglandin; uveitis